Clinical trials in Malaga – page 18

1 052 clinical trials in Malaga, Spain across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Malaga at a glance

1 052

clinical trials

Research sites4

Quick filters

1 052 trials in Malaga

Open in trial search

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Pfizer Inc.

Contact Research Centre

Breast cancer+1

Recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Iron deficiency

Recruiting

Study comparing Sucrosomial Iron and Ferric Maltol treatment for women with iron deficiency

Registered drugNo placebo

Study comparing Sucrosomial Iron and Ferric Maltol treatment for women with iron deficiency

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Sponsor:Pharmanutra S.p.A.

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Small cell lung cancer limited stage

Recruiting

Study of Tarlatamab maintenance treatment after chemotherapy and radiation therapy in patients with limited stage small cell lung cancer who cannot receive both treatments together

InvestigationalNo placebo

Study of Tarlatamab maintenance treatment after chemotherapy and radiation therapy in patients with limited stage small cell lung cancer who cannot receive both treatments together

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:Fundacion GECP

Contact Research Centre

Pulmonary arterial hypertension

Recruiting

A study of LTP001 in combination with standard treatment for adults with pulmonary arterial hypertension

Investigational

A study of LTP001 in combination with standard treatment for adults with pulmonary arterial hypertension

Investigational

Spain

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Ltp001
Sponsor:Novartis Pharma AG

Contact Research Centre

Endometrial cancer+2

Recruiting

Study of dostarlimab treatment before surgery in patients with stage II-III endometrial cancer with specific genetic markers

Registered drugNo placebo

Study of dostarlimab treatment before surgery in patients with stage II-III endometrial cancer with specific genetic markers

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Contact Research Centre

Relapsing multiple sclerosis

Recruiting

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Ocrelizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Irritable bowel syndrome

Recruiting

Study of Saccharomyces boulardii CNCM I-745 to treat symptoms in adults with non-constipated Irritable Bowel Syndrome

Registered drug

Study of Saccharomyces boulardii CNCM I-745 to treat symptoms in adults with non-constipated Irritable Bowel Syndrome

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Loperamide Hydrochloride
Sponsor:Biocodex

Contact Research Centre

Non-small cell lung cancer+2

Recruiting

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo

Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Maia Biotechnology Inc.

Contact Research Centre

Myelodysplastic syndrome

Recruiting

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo

Study of momelotinib tablets in patients with anemia caused by low-risk myelodysplastic syndrome

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Momelotinib Dihydrochloride Monohydrate
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

Registered drugNo placebo

Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Qilu Pharmaceutical Co. Ltd.

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Malaga

What the registry says about research in the country

01 Autoimmune Conditions

Research focusing on innovative treatments for cutaneous lupus erythematosus and myasthenia gravis, evaluating new therapeutic approaches to improve patient outcomes.

Lupus skin manifestations
Neuromuscular disorders
Chronic urticaria management

Studies aim to assess novel therapies' effectiveness in reducing disease activity and improving daily living activities.

02 Infectious Diseases

Innovative vaccine development studies targeting COVID-19, cytomegalovirus, and respiratory syncytial virus, focusing on prevention and immune response.

Viral infections
Vaccine combinations
Pediatric prevention

Research emphasizes safety and immunogenicity in various population groups.

03 Oncology

Advanced studies in bladder cancer, colorectal cancer, and gastric cancer, evaluating targeted therapies and combination treatments.

Non-muscle invasive treatments
Metastatic disease management
Immunotherapy approaches

Trials focus on improving survival rates and treatment responses in various cancer types.

04 Respiratory Medicine

Research examining new treatments for chronic rhinosinusitis and COPD, with emphasis on symptom management and exacerbation prevention.

Airway inflammation
Pulmonary function
Quality of life measures

Studies evaluate novel therapeutic approaches for chronic respiratory conditions.

Back to Spain All countries